Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Receives $17.00 Average Target Price from Brokerages

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) has received an average rating of “Hold” from the five analysts that are currently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and one has given a buy rating to the company. The average twelve-month target price among analysts that have covered the stock in the last year is $17.00.

Several research firms recently commented on VRCA. TD Cowen restated a “buy” rating on shares of Verrica Pharmaceuticals in a research report on Wednesday, January 7th. Zacks Research lowered shares of Verrica Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Monday, March 9th. Loop Capital set a $17.00 target price on Verrica Pharmaceuticals in a research report on Thursday, December 18th. Wall Street Zen lowered Verrica Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, February 7th. Finally, upgraded Verrica Pharmaceuticals from a “hold” rating to a “buy” rating and set a $17.00 price target on the stock in a research report on Thursday, December 18th.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Man Group plc acquired a new position in Verrica Pharmaceuticals during the fourth quarter worth $94,000. Quadrature Capital Ltd acquired a new stake in shares of Verrica Pharmaceuticals in the fourth quarter valued at about $99,000. Beck Mack & Oliver LLC purchased a new stake in shares of Verrica Pharmaceuticals during the fourth quarter worth about $100,000. Bridgeway Capital Management LLC purchased a new stake in shares of Verrica Pharmaceuticals during the third quarter worth about $52,000. Finally, XTX Topco Ltd acquired a new position in shares of Verrica Pharmaceuticals during the 4th quarter worth about $122,000. Hedge funds and other institutional investors own 42.45% of the company’s stock.

Verrica Pharmaceuticals Trading Up 3.1%

Shares of NASDAQ:VRCA opened at $4.62 on Monday. Verrica Pharmaceuticals has a 12-month low of $3.28 and a 12-month high of $9.82. The company has a market capitalization of $79.37 million, a PE ratio of -2.92 and a beta of 1.47. The business has a 50 day moving average of $6.23 and a two-hundred day moving average of $5.87. The company has a current ratio of 2.59, a quick ratio of 2.45 and a debt-to-equity ratio of 0.03.

Verrica Pharmaceuticals (NASDAQ:VRCA) last issued its quarterly earnings data on Wednesday, March 11th. The company reported ($0.51) EPS for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.08). The firm had revenue of $5.09 million for the quarter, compared to analyst estimates of $4.52 million. As a group, analysts forecast that Verrica Pharmaceuticals will post -1.46 EPS for the current year.

About Verrica Pharmaceuticals

Verrica Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of topical therapies for dermatological conditions. Its lead investigational product, VP-102, is a standardized formulation of cantharidin in a pre-measured applicator designed to treat molluscum contagiosum and common warts. Verrica’s approach emphasizes consistency of dosing and patient convenience, aiming to improve upon off‐label use of existing treatments.

Beyond VP-102, Verrica is advancing VP-103, a next‐generation topical candidate intended to optimize tolerability while maintaining efficacy against viral skin lesions.